ABS-201

Eli Lilly invested $40 million in Absci Corporation to advance ABS-201, an AI-designed injectable antibody targeting hair loss and endometriosis. The investment was part of a $100 million equity round…

Eli Lilly invested $40 million in Absci, a generative AI drug company, to develop ABS-201, an injectable antibody for baldness and endometriosis. The deal, part of a $100 million stock offering, aims …

Absci Corporation dosed the first patients in a Phase 1/2a trial of ABS-201, an AI-designed antibody for hair loss, achieving a concept-to-clinic timeline of approximately 24 months. The trial, named …